Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02905591 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
A Phase 2 study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung, sponsored by Joseph J. Cullen, MD, FACS.
- Active
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT02905591: Active Phase 2 study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung, sponsored by Joseph J. Cullen, MD, FACS.
NCT02905591 is a Phase 2 study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Joseph J. Cullen, MD, FACS. The registered enrollment target is 43 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02905591, a Phase 2 study of Non-Small Cell Lung Cancer and Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Joseph J. Cullen, MD, FACS.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy for non-small cell lung cancer. The standard therapy is radiation therapy combined with carboplatin and paclitaxel (types of chemotherapy). All subjects will receive high-dose ascorbate in addition to the standard therapy.
Primary Outcome
The proportion of participants with progressive disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at the completion of radiation and chemotherapy.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Radiation Therapy
- DRUG Ascorbic Acid
Study Locations (1)
Iowa
- Holden Comprehensive Cancer Cener - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-11-16 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What the registry record for NCT02905591 still lists
NCT02905591 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (93% lower).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT02905591 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT02905591 about?
NCT02905591 is a clinical study titled "A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC". This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy for non-small cell lung cancer. The standard therapy is radiation therapy combined with carboplatin and paclitaxel (types of chemotherapy). All subjects will receive high-dose ascorbate in addition to the stan...
What is the current status of trial NCT02905591?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2018-11-16. Estimated completion is 2027-12-31.
What conditions does trial NCT02905591 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, NSCLC, Non-Small-Cell Lung Carcinoma.
What interventions are being tested in trial NCT02905591?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Radiation Therapy (DRUG), Ascorbic Acid (DRUG).
Who is sponsoring clinical trial NCT02905591?
This trial is sponsored by Joseph J. Cullen, MD, FACS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02905591 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02905591's enrollment target sits among peer trials
43 349th of 454 higher than 104 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI